Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML)
- 31 March 2002
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 15 (1) , 105-118
- https://doi.org/10.1053/beha.2001.0193
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Detection of minimal residual disease in acute leukemia by flow cytometryCytometry, 1999
- Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic LeukemiaBlood, 1999
- A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detectionLeukemia, 1999
- Detection of abnormalities in B‐cell differentiation pattern is a useful tool to predict relapse in precursor‐B‐ALLBritish Journal of Haematology, 1999
- Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrowCytometry, 1997
- Prediction of Relapse of Pediatric Acute Myeloid Leukemia by Use of Multidimensional Flow CytometryJNCI Journal of the National Cancer Institute, 1996
- Detection of Minimal Residual Disease in Acute Myelogenous LeukemiaJournal of Pediatric Hematology/Oncology, 1995
- Acute Lymphoblastic Leukemia (ALL): Detection of Minimal Residual Disease (MRD) at Flow CytometryLeukemia & Lymphoma, 1994
- Detection of Residual Leukemia with Immunologic Methods: Technical Developments and Clinical ImplicationsLeukemia & Lymphoma, 1994
- The immunologic detection of minimal residual disease in acute leukemia [published erratum appears in Blood 1990 Nov 1;76(7):1901]Blood, 1990